AUPP807399A0 - Improved immunogenic lhrh composition and methods relating thereto - Google Patents

Improved immunogenic lhrh composition and methods relating thereto

Info

Publication number
AUPP807399A0
AUPP807399A0 AUPP8073A AUPP807399A AUPP807399A0 AU PP807399 A0 AUPP807399 A0 AU PP807399A0 AU PP8073 A AUPP8073 A AU PP8073A AU PP807399 A AUPP807399 A AU PP807399A AU PP807399 A0 AUPP807399 A0 AU PP807399A0
Authority
AU
Australia
Prior art keywords
composition
methods relating
adjuvant
animal
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP8073A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Priority to AUPP8073A priority Critical patent/AUPP807399A0/en
Publication of AUPP807399A0 publication Critical patent/AUPP807399A0/en
Priority to DE69939706T priority patent/DE69939706D1/de
Priority to AU25263/00A priority patent/AU758133B2/en
Priority to CA002660344A priority patent/CA2660344A1/en
Priority to US09/857,797 priority patent/US9579379B1/en
Priority to EP08005701A priority patent/EP1946773A3/en
Priority to EP99968288A priority patent/EP1140165B1/en
Priority to CA2359111A priority patent/CA2359111C/en
Priority to PCT/AU1999/001167 priority patent/WO2000041720A1/en
Priority to PT99968288T priority patent/PT1140165E/pt
Priority to ES99968288T priority patent/ES2317708T3/es
Priority to JP2000593330A priority patent/JP4949555B2/ja
Priority to NZ512011A priority patent/NZ512011A/xx
Priority to DK99968288T priority patent/DK1140165T3/da
Priority to AT99968288T priority patent/ATE410183T1/de
Priority to TW088123010A priority patent/TW533079B/zh
Priority to ZA200105543A priority patent/ZA200105543B/en
Priority to CY20091100002T priority patent/CY1108693T1/el
Priority to JP2011242133A priority patent/JP2012072157A/ja
Priority to US13/420,082 priority patent/US9149520B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
AUPP8073A 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto Abandoned AUPP807399A0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto
AT99968288T ATE410183T1 (de) 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
PCT/AU1999/001167 WO2000041720A1 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
ES99968288T ES2317708T3 (es) 1999-01-08 1999-12-24 Composiciones adyuvantes de saponia mejorada y metodos relacionados con las mismas.
CA002660344A CA2660344A1 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
US09/857,797 US9579379B1 (en) 1999-01-08 1999-12-24 Saponin adjuvant compositions and methods relating thereto
EP08005701A EP1946773A3 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
EP99968288A EP1140165B1 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
CA2359111A CA2359111C (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
DE69939706T DE69939706D1 (de) 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
PT99968288T PT1140165E (pt) 1999-01-08 1999-12-24 Composições de adjuvante de saponina melhoradas e métodos relacionados
AU25263/00A AU758133B2 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant composition and methods relating thereto
JP2000593330A JP4949555B2 (ja) 1999-01-08 1999-12-24 改良サポニンアジュバント組成物およびそれに関する方法
NZ512011A NZ512011A (en) 1999-01-08 1999-12-24 Improved saponin adjuvant compositions and methods relating thereto
DK99968288T DK1140165T3 (da) 1999-01-08 1999-12-24 Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
TW088123010A TW533079B (en) 1999-01-08 1999-12-27 Adjuvant compositions comprising ionic saccharides and saponins, and uses thereof
ZA200105543A ZA200105543B (en) 1999-01-08 2001-07-05 Improved saponin adjuvant compositions and methods relating thereto.
CY20091100002T CY1108693T1 (el) 1999-01-08 2009-01-07 Βελτιωμενες ανοσοενισχυτικες συνθεσεις σαπωνινης και μεθοδοι οι οποιες σχετιζονται με αυτες
JP2011242133A JP2012072157A (ja) 1999-01-08 2011-11-04 改良サポニンアジュバント組成物およびそれに関する方法
US13/420,082 US9149520B2 (en) 1999-01-08 2012-03-14 Saponin adjuvant compositions and methods relating thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto

Publications (1)

Publication Number Publication Date
AUPP807399A0 true AUPP807399A0 (en) 1999-02-04

Family

ID=3812278

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP8073A Abandoned AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto
AU25263/00A Expired AU758133B2 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant composition and methods relating thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU25263/00A Expired AU758133B2 (en) 1999-01-08 1999-12-24 Improved saponin adjuvant composition and methods relating thereto

Country Status (15)

Country Link
US (2) US9579379B1 (enExample)
EP (2) EP1140165B1 (enExample)
JP (2) JP4949555B2 (enExample)
AT (1) ATE410183T1 (enExample)
AU (2) AUPP807399A0 (enExample)
CA (2) CA2660344A1 (enExample)
CY (1) CY1108693T1 (enExample)
DE (1) DE69939706D1 (enExample)
DK (1) DK1140165T3 (enExample)
ES (1) ES2317708T3 (enExample)
NZ (1) NZ512011A (enExample)
PT (1) PT1140165E (enExample)
TW (1) TW533079B (enExample)
WO (1) WO2000041720A1 (enExample)
ZA (1) ZA200105543B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
KR20100018029A (ko) * 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
BRPI0611390A2 (pt) * 2005-06-01 2010-09-08 Pfizer Prod Inc composições de vacina e uso de composições compreendendo vacina anti-lhrh na preparação de um medicamento para tratar incontinência urinária
WO2008110912A1 (en) * 2007-03-14 2008-09-18 Pfizer Inc. Fertility regulation in horses
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
MX2012001194A (es) 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2011077309A2 (en) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Vaccine compositions
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
KR20200040899A (ko) * 2011-05-13 2020-04-20 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
JP6431920B2 (ja) 2013-09-17 2018-11-28 オービーアイ ファーマ，インコーポレイテッド 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用
WO2015042423A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Vaccine
KR20160077214A (ko) 2013-12-16 2016-07-01 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CA2939572A1 (en) 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
SG11201607258SA (en) 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
ES2950822T3 (es) * 2015-01-16 2023-10-13 Zoetis Services Llc Vacuna contra la enfermedad de fiebre aftosa
JP2018521016A (ja) 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
KR102800419B1 (ko) 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
MY200886A (en) 2016-04-22 2024-01-22 Obi Pharma Inc Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
JP2019527690A (ja) 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
EP4240410A1 (en) 2020-11-04 2023-09-13 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
EP4479088A1 (en) 2022-02-14 2024-12-25 University of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof
AU2024296166A1 (en) * 2023-07-07 2025-09-25 Ouro Fino Saúde Animal Ltda Modified gnrh peptide and its conjugate for mammalian immunocastration, manufacturing method, composition and kit
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1924304C3 (de) * 1969-05-13 1980-07-17 Bayer Ag, 5090 Leverkusen Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
AU602187B2 (en) * 1987-01-14 1990-10-04 Commonwealth Scientific And Industrial Research Organisation Anti-reproductive hormone
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
US4892830A (en) * 1987-04-02 1990-01-09 Baylor College Of Medicine Environmentally controlled in vitro incubator
GB2228262B (en) 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
CA2040441C (en) * 1989-08-25 1998-03-31 Gregory J. Russell-Jones Fusion proteins
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU7468196A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
AUPP060097A0 (en) * 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response

Also Published As

Publication number Publication date
DE69939706D1 (de) 2008-11-20
CA2359111A1 (en) 2000-07-20
CY1108693T1 (el) 2012-05-23
US20120251566A1 (en) 2012-10-04
JP2012072157A (ja) 2012-04-12
TW533079B (en) 2003-05-21
CA2359111C (en) 2014-02-18
WO2000041720A8 (en) 2000-11-09
EP1946773A2 (en) 2008-07-23
ES2317708T3 (es) 2009-04-16
AU2526300A (en) 2000-08-01
NZ512011A (en) 2002-12-20
JP2002534480A (ja) 2002-10-15
WO2000041720A1 (en) 2000-07-20
EP1140165B1 (en) 2008-10-08
JP4949555B2 (ja) 2012-06-13
EP1946773A3 (en) 2008-07-30
ZA200105543B (en) 2003-01-22
US9579379B1 (en) 2017-02-28
US9149520B2 (en) 2015-10-06
PT1140165E (pt) 2009-01-13
AU758133B2 (en) 2003-03-13
ATE410183T1 (de) 2008-10-15
CA2660344A1 (en) 2000-07-20
EP1140165A1 (en) 2001-10-10
EP1140165A4 (en) 2005-01-05
DK1140165T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
AUPP807399A0 (en) Improved immunogenic lhrh composition and methods relating thereto
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
CA2217178A1 (en) Vaccines containing a saponin and a sterol
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
CA2187974A1 (en) Newcastle disease virus combination vaccine
PT1149589E (pt) Adjuvantes proteínicos
PT2184071T (pt) Solubilização de polisacáridos capsulares e vacinas combinadas
AU4324896A (en) Vaccine adjuvants
GB2341801B (en) Formulation
NZ287385A (en) Antigenic preparation comprising the catalase of helicobacter bacteria and vaccines used to treat helicobacter infection
AU2238597A (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
WO2004026024B1 (en) Vaccine compositions and adjuvant
AU4063095A (en) Avian herpesvirus-based live recombinant avian vaccine, in particular against Gumboro disease
CA2266486A1 (en) Rotavirus vaccine formulations
CA2182274A1 (en) Antigenic preparation for treatment or prevention of helicobacter infection
GB9422990D0 (en) Immunogenic compositions
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
EP0315153A3 (en) Vaccine adjuvant
EP0888777A3 (en) Recombinant bovine herpesvirus type 1 polyptpetides and vaccines
EP0326111A3 (en) Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002032455A3 (en) Vaccine

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 2526300

Country of ref document: AU